接受长效卡博特韦暴露前预防的男男性行为者及跨性别女性HIV感染特征:HPTN 083研究
HPTN 083试验显示长效卡博特韦(CAB-LA)在预防HIV上优于TDF/FTC。早期病毒载量检测有助于更早发现感染。
要点
- CAB-LA组突破性感染中部分病毒载量低或药物浓度不足,4例感染发生在按时注射且血药浓度符合预期者。
- CAB暴露可延长病毒抑制并延迟抗体产生,导致HIV诊断延迟和耐药风险增加。
- 病毒载量检测有助于早期发现CAB-LA预防下的HIV感染,应及时启动抗逆转录病毒治疗。
核心结论
- CAB-LA预防下的HIV突破性感染常伴低或无法定量的研究药物浓度,CAB暴露与病毒抑制延长和抗体表达延迟相关。
- 延迟HIV诊断可导致未察觉感染时继续给予CAB、延迟抗逆转录病毒治疗及耐药出现,病毒载量检测可更早发现多数感染。
研究设计与样本
- 对HPTN 083试验盲法阶段发生的HIV感染进行回顾性检测,包括HIV检测、病毒载量检测、研究药物定量和HIV耐药检测。
主要发现
- CAB组12例新发感染中5例、TDF/FTC组39例中37例感染与低或无法定量的研究药物浓度相关。
- 4例感染发生在按时接受CAB-LA注射且血浆CAB浓度符合预期的情况下。
- CAB暴露与病毒抑制延长和抗体表达延迟相关。
临床怎么用
- 对接受CAB-LA暴露前预防者,应通过病毒载量检测早期识别HIV感染,避免延迟诊断。
- 一旦发现HIV感染,应及时启动抗逆转录病毒治疗,以减少耐药发生并改善临床结局。
局限性
- 本研究为对HPTN 083试验盲法阶段感染病例的回顾性分析,需进一步研究明确CAB-LA保护的相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with men. We characterized HIV infections that occurred in the blinded phase of HPTN 083. METHODS: Retrospective testing included HIV testing, viral load testing, quantification of study drugs, and HIV drug resistance testing. RESULTS: Fifty-eight infections were evaluated, including 51 incident infections (12 in CAB arm and 39 in TDF/FTC arm). In many cases (5 in CAB arm and 37 in TDF/FTC arm), infection was associated with low or unquantifiable study drug concentrations. In 4 cases, infection occurred with on-time CAB-LA injections and expected plasma CAB concentrations. CAB exposure was associated with prolonged viral suppression and delayed antibody expression. In some cases, delayed HIV diagnosis resulted in CAB provision to participants with undetected infection, delayed antiretroviral therapy, and emergence of drug resistance; most of these infections would have been detected earlier with viral load testing. CONCLUSIONS: Early detection of HIV infection and prompt antiretroviral therapy initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. Further studies are needed to elucidate the correlates of HIV protection in persons receiving CAB-LA.
引用
- Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 2021. PMID: 33740057. doi:10.1093/infdis/jiab152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。